Clinical Trial Update: CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients [Phase 4]

View source ↗

Summary

Phase 4 CARE-2 trial evaluating calcium acetate (PhosLo) and sevelamer (Renagel) for heart calcification in dialysis patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arteriosclerosis
• Calcinosis
• Hyperparathyroidism

Drugs mentioned

• PhosLo (Calcium Acetate) (Calcium acetate)
• Renagel (Sevelamer) (Sevelamer)

Snippet

Sponsor: Nabi Biopharmaceuticals | Conditions: Calcinosis, Arteriosclerosis | Phase 4 | Status: COMPLETED